Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece

• Asıl Yazarlar: Georgia Ragia (Yazar), Anthi Maslarinou (Yazar), Natalia Atzemian (Yazar), Eirini Biziota (Yazar), Triantafyllia Koukaki (Yazar), Charalampia Ioannou (Yazar), Ioanna Balgkouranidou (Yazar), George Kolios (Yazar), Stylianos Kakolyris (Yazar), Nikolaos Xenidis (Yazar), Kyriakos Amarantidis (Yazar), Vangelis G. Manolopoulos (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2023-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Introduction: Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism. DPYD gene variants seriously affect DPD activity and are well validated predictors of FP-associated toxicity. DPYD variants rs3918290, rs55886062,...